Literature DB >> 19996828

Effect of photodynamic therapy alone or combined with posterior subtenon triamcinolone acetonide or intravitreal bevacizumab on choroidal hypofluorescence by indocyanine green angiography.

Yoshiyuki Hatta1, Kohei Ishikawa, Hiroaki Nishihara, Shinsuke Ozawa, Yasuki Ito, Hiroko Terasaki.   

Abstract

PURPOSE: Choroidal hypofluorescence has been reported beneath the photodynamic therapy (PDT) site in clinical studies. We evaluated the choroidal hypofluorescence after combined PDT with posterior subtenon injection of triamcinolone acetonide or PDT with an intravitreal injection of bevacizumab for age-related macular degeneration.
METHODS: Two hundred and forty-two eyes with a subfoveal choroidal neovascularization caused by age-related macular degeneration were studied. Ninety-two eyes underwent PDT alone, 90 eyes underwent PDT with sub-Tenon injection of triamcinolone acetonide, and 60 eyes underwent PDT with intravitreal injection of bevacizumab. Verteporfin-induced choroidal hypoperfusion was determined by indocyanine green angiograms. The intensity of the diffuse fluorescence within the PDT site away from the choroidal neovascularization lesion and from the normal retina just peripheral to the optic disk was measured by densitometry (Topcon IMAGEnet computer system, Topcon, Tokyo, Japan) in the indocyanine green angiogram images obtained at 10 minutes 3 months after the PDT. The ratio of the average brightness of the retina within the PDT area to that of the retina peripheral to the optic disk (irradiated/nonirradiated retinal brightness ratio) was calculated for each angiogram.
RESULTS: The irradiated/nonirradiated retinal brightness ratio of the angiograms was 0.96 in the PDT-alone group, 0.85 in the sub-Tenon injection of triamcinolone acetonide-PDT group, and 0.89 in the intravitreal injection of bevacizumab-PDT group (Kruskal-Wallis H test, P < 0.05).
CONCLUSION: The degree of choroidal hypofluorescence in the indocyanine green angiogram images 3 months after PDT in the sub-Tenon injection of triamcinolone acetonide and intravitreal injection of bevacizumab group was higher than that of PDT-alone group. Sub-Tenon injection of triamcinolone acetonide and intravitreal injection of bevacizumab can prolong the duration of the choroidal hypofluorescence after PDT.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19996828     DOI: 10.1097/IAE.0b013e3181bcedbe

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  11 in total

1.  Combined photodynamic therapy with verteporfin and intravitreal anti-vascular endothelial growth factor therapy for chronic central serous chorioretinopathy.

Authors:  J Fernando Arevalo; Juan V Espinoza
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-12-06       Impact factor: 3.117

2.  Focal macular electroretinograms after photodynamic therapy combined with intravitreal bevacizumab.

Authors:  Kohei Ishikawa; Hiroaki Nishihara; Shinsuke Ozawa; Chang-Hua Piao; Yasuki Ito; Mineo Kondo; Hiroko Terasaki
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-10-31       Impact factor: 3.117

3.  The role of anti-inflammatory agents in age-related macular degeneration (AMD) treatment.

Authors:  Y Wang; V M Wang; C-C Chan
Journal:  Eye (Lond)       Date:  2010-12-24       Impact factor: 3.775

4.  Single-session combined photodynamic therapy with verteporfin and intravitreal anti-vascular endothelial growth factor therapy for chronic central serous chorioretinopathy: a pilot study at 12-month follow-up.

Authors:  J Fernando Arevalo; Juan V Espinoza
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-03-30       Impact factor: 3.117

Review 5.  Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.

Authors:  Sharon D Solomon; Kristina Lindsley; Satyanarayana S Vedula; Magdalena G Krzystolik; Barbara S Hawkins
Journal:  Cochrane Database Syst Rev       Date:  2014-08-29

6.  Oscillatory photodynamic therapy for choroidal neovascularization and central serous retinopathy; a pilot study.

Authors:  Gholam A Peyman; Michael Tsipursky; Nariman Nassiri; Mandi Conway
Journal:  J Ophthalmic Vis Res       Date:  2011-07

7.  Photodynamic Therapy and Intravitreal Bevacizumab with Versus without Triamcinolone for Neovascular Age-related Macular Degeneration; a Randomized Clinical Trial.

Authors:  Niloofar Piri; Hamid Ahmadieh; Ramin Taei; Masoud Soheilian; Reza Karkhaneh; Alireza Lashay; Faegheh Golbafian; Mehdi Yaseri; Mohammad Riazi-Esfahani
Journal:  J Ophthalmic Vis Res       Date:  2014 Oct-Dec

8.  Comparison between 1-year outcomes of aflibercept with and without photodynamic therapy for polypoidal choroidal vasculopathy: Retrospective observation study.

Authors:  Kei Takayama; Hiroki Kaneko; Keiko Kataoka; Kyoko Hattori; Eimei Ra; Taichi Tsunekawa; Hiroshi Fukukita; Fuminori Haga; Yasuki Ito; Hiroko Terasaki
Journal:  PLoS One       Date:  2017-05-03       Impact factor: 3.240

9.  Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.

Authors:  Sharon D Solomon; Kristina Lindsley; Satyanarayana S Vedula; Magdalena G Krzystolik; Barbara S Hawkins
Journal:  Cochrane Database Syst Rev       Date:  2019-03-04

10.  Rescue effects of intravitreal aflibercept in the treatment of neovascular age-related macular degeneration.

Authors:  Ning-Yi Hsia; Chun-Ju Lin; Jane-Ming Lin; Wen-Lu Chen; Peng-Tai Tien; Yi-Hao Ho; Chung-Yuan Kuo; Yi-Yu Tsai
Journal:  Taiwan J Ophthalmol       Date:  2015-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.